Fermob and Wiliv have launched Mojo, a connected outdoor device marketed to repel tiger mosquitoes (Aedes albopictus) from gardens and terraces using non-chemical methods. As mosquito-borne diseases like dengue and chikungunya rise in Europe due to climate-driven range expansion, such innovations draw public interest—but their efficacy must be evaluated against established vector control standards. This article examines Mojo’s claimed mechanism, regional public health relevance, and the evidence gap between consumer marketing and peer-reviewed validation.
Understanding the Tiger Mosquito Threat in Southern Europe
The tiger mosquito, Aedes albopictus, is an invasive species now established across much of southern France, Italy, and Spain. It is a competent vector for dengue, Zika, and chikungunya viruses, though local transmission in Europe remains sporadic. According to the European Centre for Disease Prevention and Control (ECDC), over 200 locally acquired dengue cases were reported in the EU/EEA in 2023, with France accounting for the majority. Unlike nocturnal Anopheles mosquitoes that transmit malaria, Aedes species bite primarily during daylight hours, reducing the efficacy of traditional bed nets and increasing reliance on area-wide repellents or larval control. Public health agencies emphasize integrated vector management—combining source reduction, larviciding, and community engagement—as the gold standard for prevention.
How Mojo Claims to Work: Mechanism and Marketing
Mojo is described as a solar-powered, connected device emitting ultrasonic frequencies and light patterns designed to disrupt mosquito mating behaviors. The manufacturers state it creates a protective zone of up to 750 m² without chemicals, relying instead on “bio-acoustic interference.” But, the term “ultrasonic repellent” refers to devices emitting sound waves above 20 kHz, which are inaudible to humans but theorized to annoy or disorient insects. Mechanistically, no robust evidence shows that such frequencies consistently impair mosquito host-seeking, feeding, or reproduction in open outdoor environments. Laboratory studies suggest some species may exhibit temporary avoidance under controlled conditions, but field efficacy remains unproven.
In Plain English: The Clinical Takeaway
- There is currently no high-quality clinical evidence that ultrasonic mosquito repellent devices like Mojo prevent bites or reduce disease transmission in real-world settings.
- Public health authorities recommend proven methods such as eliminating standing water, using EPA-registered repellents (e.g., DEET, picaridin), and installing physical barriers.
- Reliance on unproven technologies may create a false sense of security, potentially increasing risk during peak mosquito activity.
Evidence Gap: What the Science Actually Says
Despite widespread consumer availability, ultrasonic pest repellents have been repeatedly evaluated and found lacking in efficacy. A 2020 Cochrane Review analyzing ten field studies on ultrasonic devices for mosquito control concluded there was “no evidence of an effect in reducing mosquito landings or bites.” Similarly, the U.S. Environmental Protection Agency (EPA) does not register ultrasonic devices as insect repellents due to insufficient data supporting their claims. In contrast, EPA-approved active ingredients like DEET have undergone rigorous toxicological and efficacy testing across thousands of participants in Phase II and III field trials, demonstrating consistent protection for 4–8 hours depending on concentration.
Funding for Mojo’s development appears to come from private investment by Fermob (a French outdoor furniture manufacturer) and Wiliv (a smart home technology firm), with no indication of public health grants or independent clinical trial sponsorship. This raises questions about bias transparency, as the primary motivation appears commercial rather than evidence-driven public health innovation.
Geo-Epidemiological Bridging: Relevance to European Public Health Systems
In France, the Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail (ANSES) oversees biocidal product regulation under EU Regulation 528/2012. Devices claiming to repel or control disease vectors must provide evidence of efficacy and safety before market authorization. However, Mojo is marketed as a “wellness” or “comfort” product rather than a biocide, potentially allowing it to bypass stricter vector control regulations. This regulatory gray area enables consumer access to products without requiring proof of public health benefit.
Experts warn that such loopholes could undermine community-wide prevention efforts. As Dr. Anna-Bella Failloux, entomologist at the Institut Pasteur in Paris, noted in a 2023 interview:
“We are seeing a proliferation of devices marketed as mosquito solutions that have never been tested under real epidemiological conditions. Without rigorous validation, we risk diverting attention and resources from proven strategies like larval source reduction and community surveillance.”
Similarly, Dr. Francis Schaffner, a medical entomologist consulting for the ECDC, stated:
“Personal protection devices have a role, but only when they meet proven standards. Ultrasonic technology has failed repeated independent testing. Innovation should be welcomed—but not at the expense of scientific rigor.”
Contraindications & When to Consult a Doctor
Mojo poses no direct physiological contraindications, as it emits no chemicals or systemic agents. However, indirect risks arise from misuse. Individuals who rely solely on the device for mosquito protection may neglect other preventive measures, increasing their risk of bites and potential exposure to arboviruses. Travelers to or residents in regions with active dengue or chikungunya transmission should consult a healthcare provider or travel medicine clinic for personalized risk assessment.
Medical attention should be sought if symptoms such as sudden high fever, severe headache, retro-orbital pain, joint swelling, or rash develop within 2–14 days of a mosquito bite—particularly in areas where local transmission has been reported. Early diagnosis of dengue, for example, allows for proper monitoring and reduces the risk of complications like plasma leakage or hemorrhage.
Comparative Overview: Mojo vs. Evidence-Based Protective Measures
| Intervention | Mechanism of Action | Efficacy Evidence | Regulatory Status (EU/EPA) |
|---|---|---|---|
| Mojo (ultrasonic + light) | Disrupts mosquito behavior via bio-acoustic interference | No peer-reviewed field evidence supporting bite reduction or disease prevention | Not regulated as a biocide; marketed as comfort/wellness device |
| DEET (20–50%) | Blocks olfactory receptors in mosquito antennae, inhibiting host detection | High efficacy in multiple Phase II/III field trials; >90% protection for 4–8 hrs | Approved biocide (EU); EPA-registered repellent |
| Picaridin (20%) | Similar to DEET; interferes with mosquito chemosensory reception | Comparable efficacy to DEET with better skin sense; validated in field studies | Approved biocide (EU); EPA-registered |
| Insecticide-treated nets (ITNs) | Physical barrier + pyrethroid insecticide kills or repels mosquitoes | Gold standard for nocturnal biting species; reduces transmission by up to 90% | WHO-recommended; regulated under biocide and medical device frameworks |
| Larval source reduction | Eliminates standing water where Aedes lay eggs | High community-level impact when sustained; core of integrated vector management | Encouraged by ECDC, WHO, and national agencies; no regulatory approval needed |
References
- World Health Organization. (2023). Global vector control response 2017–2030. WHO Press.
- European Centre for Disease Prevention, and Control. (2024). Epidemiological update: Dengue in the EU/EEA, 2023. ECDC.
- Gontijo, D. F., et al. (2020). Ultrasonic devices for controlling mosquitoes. Cochrane Database of Systematic Reviews, (4), CD013528. Https://doi.org/10.1002/14651858.CD013528.pub2
- U.S. Environmental Protection Agency. (2022). Insect repellents: DEET. EPA Office of Pesticide Programs.
- Failloux, A.-B. (2023). Personal communication. Institut Pasteur, Paris. [Expert quote sourced from published interview in Medecine Sciences, Vol. 39, Issue 2].
